Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

13 Canadian Crypto ETFs (Updated 2024)

When is the Starlink IPO Date and Can You Invest? (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

Leigh Goehring: Gold's "Massive Bull Market" Just Starting; Uranium and Copper Outlook

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

How Could Trump's US Election Win Affect the Gold Price?

Top 4 Largest Lithium Reserves by Country (Updated 2024)

Trending Press Releases

McDermitt PFS Demonstrates Multi-Decade Competitive Source of US Lithium Carbonate

OSISKO METALS EXPANDS LEADERSHIP TEAM AND ANNOUNCES C$100 MILLION BOUGHT DEAL FINANCING

Osisko Metals Announces Significant Increase in Mineral Resources at Gaspé Copper

Silver47 Drills 2.48m of 14.95 g/t Gold, 249.50 g/t Silver, 21.97% Zinc, 7.03% Lead, 0.42% Copper at Its Red Mountain Project, Alaska

Production and Revenue Growth at Alta Mesa Uranium Project, Texas

Announcement by Cyclone Metals Ltd

More Press Releases
Trending Companies

Silver47 Exploration

AGA:CC

Purpose Bitcoin ETF

BTCC:CA

Osisko Metals: Leading the Charge in Base Metal Investments

OM:CA

Syntheia

SYAI:CC
More Companies
Trending Reports

2024 Gold Outlook Report

2024 Lithium Market Outlook

2024 AI Market Outlook Report

Silver Price Forecast - What Happened And Where Do We Go From Here?

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Cellectar Biosciences Inc.

NASDAQ:CLRB
Press Releases

Cellectar Granted Japanese Patent for CLR 131

Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma

FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Interactive Chart

×